Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives $5.50 Average Target Price from Brokerages

Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) have received an average rating of “Buy” from the seven analysts that are covering the firm, MarketBeat.com reports. Seven analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $5.3333.

A number of analysts have recently weighed in on RVPH shares. Wall Street Zen raised Reviva Pharmaceuticals to a “sell” rating in a research note on Saturday, August 16th. D. Boral Capital cut their target price on Reviva Pharmaceuticals from $3.00 to $2.00 and set a “buy” rating on the stock in a research note on Friday. Maxim Group cut their target price on Reviva Pharmaceuticals from $5.00 to $2.00 and set a “buy” rating on the stock in a research note on Friday, August 15th. Citigroup reissued a “buy” rating on shares of Reviva Pharmaceuticals in a research note on Friday, August 15th. Finally, Roth Capital reissued a “buy” rating and issued a $3.00 target price (down from $7.00) on shares of Reviva Pharmaceuticals in a research note on Monday, August 18th.

Institutional Investors Weigh In On Reviva Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Ameriprise Financial Inc. purchased a new stake in shares of Reviva Pharmaceuticals during the fourth quarter valued at $84,000. BluePointe Capital Management LLC boosted its position in shares of Reviva Pharmaceuticals by 354.7% during the first quarter. BluePointe Capital Management LLC now owns 47,185 shares of the company’s stock valued at $45,000 after buying an additional 36,807 shares during the last quarter. NewEdge Advisors LLC purchased a new stake in shares of Reviva Pharmaceuticals during the first quarter valued at $58,000. XTX Topco Ltd purchased a new stake in shares of Reviva Pharmaceuticals during the second quarter valued at $31,000. Finally, Private Advisor Group LLC purchased a new stake in shares of Reviva Pharmaceuticals during the first quarter valued at $191,000. 63.18% of the stock is owned by hedge funds and other institutional investors.

Reviva Pharmaceuticals Trading Up 15.3%

NASDAQ RVPH opened at $0.31 on Thursday. The company has a market cap of $21.31 million, a P/E ratio of -0.47 and a beta of -0.04. The company has a fifty day simple moving average of $0.45 and a 200 day simple moving average of $0.67. Reviva Pharmaceuticals has a 12-month low of $0.25 and a 12-month high of $4.28.

Reviva Pharmaceuticals (NASDAQ:RVPH) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.03. Sell-side analysts predict that Reviva Pharmaceuticals will post -0.97 EPS for the current year.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.